Oruka Therapeutics, Inc. Net Cash Provided by (Used in) Investing Activities, Continuing Operations
Oruka Therapeutics, Inc. (ORKA) reported Net Cash Provided by (Used in) Investing Activities, Continuing Operations of $3.05 million for the 3-month period ending 2018-03-31, per its 10-Q filed 2018-05-08.
Discontinued › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations · last filed 2018-05-08
- Oruka Therapeutics, Inc. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2018-03-31 was $3.05M, a 1.36% increase year-over-year.
- Oruka Therapeutics, Inc. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-12-31 was $4.75M, a 50.86% increase year-over-year.
- Oruka Therapeutics, Inc. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-09-30 was -$932.00K.
- Oruka Therapeutics, Inc. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-06-30 was $6.10M.
- Oruka Therapeutics, Inc. net cash provided by (used in) investing activities, continuing operations for fiscal 2017 was $12.93M.
- Oruka Therapeutics, Inc. net cash provided by (used in) investing activities, continuing operations for fiscal 2016 was -$16.41M.
- Oruka Therapeutics, Inc. net cash provided by (used in) investing activities, continuing operations for fiscal 2015 was -$11.00K.
- Oruka Therapeutics, Inc. net cash provided by (used in) investing activities, continuing operations for fiscal 2014 was -$19.00K.
| Period end | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 3 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 6 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 9 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 12 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 147 month |
|---|---|---|---|---|---|
| 2018-03-31 | $3.05M 10-Q · filed 2018-05-08 | $7.80M derived: sum of 2 quarters · filed 2018-05-08 | $6.87M derived: sum of 3 quarters · filed 2018-05-08 | $12.97M derived: sum of 4 quarters · filed 2018-05-08 | |
| 2017-12-31 | $4.75M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-22 | $3.82M derived: sum of 2 quarters · filed 2018-03-22 | $9.92M derived: sum of 3 quarters · filed 2018-03-22 | $12.93M 10-K · filed 2018-03-22 | |
| 2017-09-30 | -$932.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | $5.17M derived: sum of 2 quarters · filed 2017-11-09 | $8.18M 10-Q · filed 2017-11-09 | $11.32M derived: sum of 4 quarters · filed 2018-05-08 | |
| 2017-06-30 | $6.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-03 | $9.11M 10-Q · filed 2017-08-03 | $12.26M derived: sum of 3 quarters · filed 2018-05-08 | $9.71M derived: sum of 4 quarters · filed 2018-05-08 | |
| 2017-03-31 | $3.01M 10-Q · filed 2018-05-08 | $6.16M derived: sum of 2 quarters · filed 2018-05-08 | $3.61M derived: sum of 3 quarters · filed 2018-05-08 | -$8.20M derived: sum of 4 quarters · filed 2018-05-08 | |
| 2016-12-31 | $3.15M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-22 | $600.00K derived: sum of 2 quarters · filed 2018-03-22 | -$11.21M derived: sum of 3 quarters · filed 2018-03-22 | -$16.41M 10-K · filed 2018-03-22 | |
| 2016-09-30 | -$2.55M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | -$14.36M derived: sum of 2 quarters · filed 2017-11-09 | -$19.56M 10-Q · filed 2017-11-09 | -$19.56M derived: sum of 4 quarters · filed 2017-11-09 | |
| 2016-06-30 | -$11.81M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-03 | -$17.01M 10-Q · filed 2017-08-03 | -$17.02M derived: sum of 3 quarters · filed 2017-08-03 | -$17.02M derived: sum of 4 quarters · filed 2017-08-03 | |
| 2016-03-31 | -$5.20M 10-Q · filed 2017-05-15 | -$5.20M derived: sum of 2 quarters · filed 2017-05-15 | -$5.21M derived: sum of 3 quarters · filed 2017-05-15 | -$5.21M derived: sum of 4 quarters · filed 2017-05-15 | |
| 2015-12-31 | -$2.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-21 | -$4.00K derived: sum of 2 quarters · filed 2017-03-21 | -$9.00K derived: sum of 3 quarters · filed 2017-03-21 | -$11.00K 10-K · filed 2017-03-21 | |
| 2015-09-30 | -$2.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-14 | -$7.00K derived: sum of 2 quarters · filed 2016-11-14 | -$9.00K 10-Q · filed 2016-11-14 | -$23.00K derived: sum of 4 quarters · filed 2016-11-14 | |
| 2015-06-30 | -$5.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-09 | -$7.00K 10-Q · filed 2016-08-09 | -$21.00K derived: sum of 3 quarters · filed 2016-08-09 | -$21.00K derived: sum of 4 quarters · filed 2016-08-09 | |
| 2015-03-31 | -$2.00K 10-Q · filed 2016-05-11 | -$16.00K derived: sum of 2 quarters · filed 2016-05-11 | -$16.00K derived: sum of 3 quarters · filed 2016-05-11 | ||
| 2014-12-31 | -$14.00K derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-17 | -$14.00K derived: sum of 2 quarters · filed 2016-03-17 | -$19.00K 10-K · filed 2016-03-17 | ||
| 2014-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-12 | -$5.00K 10-Q · filed 2015-11-12 | |||
| 2014-06-30 | -$5.00K 10-Q · filed 2015-08-11 | ||||
| 2014-03-31 | $45.02M 10-Q · filed 2014-05-13 | ||||
| 2013-12-31 | -$4.00K derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-19 | -$15.00K derived: sum of 2 quarters · filed 2015-03-19 | -$23.00K derived: sum of 3 quarters · filed 2015-03-19 | -$32.00K 10-K · filed 2015-03-19 | |
| 2013-09-30 | -$11.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-12 | -$19.00K derived: sum of 2 quarters · filed 2014-11-12 | -$28.00K 10-Q · filed 2014-11-12 | ||
| 2013-06-30 | -$8.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-13 | -$17.00K 10-Q · filed 2014-08-13 | |||
| 2013-03-31 | -$9.00K 10-Q · filed 2014-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Veradermics, Inc (MANE) | United States | $4.839B |